» Articles » PMID: 20225891

Membrane Topological Analysis of the Proton-coupled Folate Transporter (PCFT-SLC46A1) by the Substituted Cysteine Accessibility Method

Overview
Journal Biochemistry
Specialty Biochemistry
Date 2010 Mar 16
PMID 20225891
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

The proton-coupled folate transporter (PCFT) mediates intestinal folate absorption. Loss-of-function mutations in this gene are the molecular basis for the autosomal recessive disorder, hereditary folate malabsorption. In this study, the substituted cysteine accessibility method was utilized to localize extra- or intracellular loops connecting predicted PCFT transmembrane domains. Cysteine-less PCFT was generated by replacement of all seven cysteine residues with serine and was shown to be functional, following which cysteine residues were introduced into predicted loops. HeLa cells, transiently transfected with these PCFT mutants, were then labeled with an impermeant, cysteine-specific biotinylation reagent (MTSEA-biotin) with or without permeabilization of cells. The biotinylated proteins were precipitated by streptavidin beads and assessed by Western blotting analysis. The biotinylation of PCFT was further confirmed by blocking cysteine residues with impermeant 2-sulfonatoethyl methanethiosulfonate. Two extracellular cysteine residues (66, 298) present in WT-PCFT were not biotinylated; however, in the absence of either one, biotinylation occurred. Likewise, biotinylation occurred after treatment with beta-mercaptoethanol. Taken together, these analyses establish a PCFT secondary structure of 12 transmembrane domains with the N- and C- termini directed to the cytoplasm. The data indicate further that there is a disulfide bridge, which is not required for function, between the native C66 and C298 residues in the first and fourth transmembrane domains, respectively.

Citing Articles

Biology and therapeutic applications of the proton-coupled folate transporter.

Matherly L, Schneider M, Gangjee A, Hou Z Expert Opin Drug Metab Toxicol. 2022; 18(10):695-706.

PMID: 36239195 PMC: 9637735. DOI: 10.1080/17425255.2022.2136071.


The evolving biology of the proton-coupled folate transporter: New insights into regulation, structure, and mechanism.

Hou Z, Gangjee A, Matherly L FASEB J. 2022; 36(2):e22164.

PMID: 35061292 PMC: 8978580. DOI: 10.1096/fj.202101704R.


A proton-coupled folate transporter mutation causing hereditary folate malabsorption locks the protein in an inward-open conformation.

Zhan H, Najmi M, Lin K, Aluri S, Fiser A, Goldman I J Biol Chem. 2020; 295(46):15650-15661.

PMID: 32893190 PMC: 7667981. DOI: 10.1074/jbc.RA120.014757.


Identification of the amino acid residue responsible for the myricetin sensitivity of human proton-coupled folate transporter.

Yamashiro T, Yasujima T, Ohta K, Inoue K, Yuasa H Sci Rep. 2019; 9(1):18105.

PMID: 31792273 PMC: 6889420. DOI: 10.1038/s41598-019-54367-9.


Substitutions that lock and unlock the proton-coupled folate transporter (PCFT-SLC46A1) in an inward-open conformation.

Aluri S, Zhao R, Lin K, Shin D, Fiser A, Goldman I J Biol Chem. 2019; 294(18):7245-7258.

PMID: 30858177 PMC: 6509503. DOI: 10.1074/jbc.RA118.005533.


References
1.
KROGH A, Larsson B, von Heijne G, Sonnhammer E . Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol. 2001; 305(3):567-80. DOI: 10.1006/jmbi.2000.4315. View

2.
Geller J, Kronn D, Jayabose S, Sandoval C . Hereditary folate malabsorption: family report and review of the literature. Medicine (Baltimore). 2002; 81(1):51-68. DOI: 10.1097/00005792-200201000-00004. View

3.
Thiriot D, Sievert M, Ruoho A . Identification of human vesicle monoamine transporter (VMAT2) lumenal cysteines that form an intramolecular disulfide bond. Biochemistry. 2002; 41(20):6346-53. DOI: 10.1021/bi015779j. View

4.
Liu X, Matherly L . Analysis of membrane topology of the human reduced folate carrier protein by hemagglutinin epitope insertion and scanning glycosylation insertion mutagenesis. Biochim Biophys Acta. 2002; 1564(2):333-42. DOI: 10.1016/s0005-2736(02)00467-4. View

5.
Vogelzang N, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P . Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21(14):2636-44. DOI: 10.1200/JCO.2003.11.136. View